Log in

140410 Mezzion Pharma Co., Ltd. KRX · South Korea

Mezzion Pharma Co. (140410) news

Mezzion Pharma Co., Ltd. is a public biotech or pharmaceutical company listed on KRX under the ticker 140410, recorded under South Korea. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Mezzion Pharma Co. news

We have not published a story on Mezzion Pharma Co. yet. When there is news, it will appear here.

Questions about Mezzion Pharma Co.

What is the ticker symbol of Mezzion Pharma Co.?

Mezzion Pharma Co., Ltd. trades under the ticker 140410 on KRX.

Where is Mezzion Pharma Co. listed?

Mezzion Pharma Co., Ltd. is listed on KRX.

Which country or territory is Mezzion Pharma Co. listed under?

Our directory records Mezzion Pharma Co., Ltd. under South Korea.

What does Mezzion Pharma Co. do?

Our directory classifies Mezzion Pharma Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Mezzion Pharma Co.?

The ISIN recorded for Mezzion Pharma Co., Ltd. is KR7140410002.

Does aibio.space cover Mezzion Pharma Co.?

aibio.space lists Mezzion Pharma Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Mezzion Pharma Co.?

Companies in our directory listed in the same country and business area as Mezzion Pharma Co.: Cosmax BTI, SK Biopharmaceuticals Co., Oscotec, KOREA PHARMA Co., WooGene B&G Co., Aptabio Therapeutics.

Investor discussion: Mezzion Pharma Co.

Members talk about Mezzion Pharma Co. (140410). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open KRX:140410 on TradingView.

Listing details

Mezzion Pharma Co., Ltd. is a public biotech or pharmaceutical company listed on KRX under the ticker 140410, recorded under South Korea. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Mezzion Pharma Co., Ltd.
Ticker
140410
Listing
KRX
Country or territory
South Korea
Business scope
Pharmaceuticals: Major
ISIN
KR7140410002
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.